Since its discovery in 1982, Helicobacter pylori (H. pylori) has attracted dramatic attention from researchers, physicians and pharmaceutical companies due to its ability to cause gastritis, peptic ulcers and gastric and hepatic carcinoma. The infections with H. pylori are considered the most widely spread infections worldwide with an estimated rate of more than 50% of the world population in the developing countries.
Many attempts have been designed to investigate for therapeutic options to the bacterium including, herbals, biotech and molecular based products. However, very few of them provided promising data. So far, the vaccination approach for example has shown limited data in animal models and still not promising to be used as alternative.
Recently, the use of camel based products in improving human health has been dramatically emerged.
Several studies have shown superior benefits of camel components in the treatment of various gastrointestinal infectious diseases for example, E. coli and Hepatitis C and Rota viruses.
Camel milk components, immunoglobulins and other proteins of the innate immune system have shown great potential as biological antimicrobial agents due to their selectivity, availability, safety in addition to their stability in extreme conditions like low pH and high temperatures making them potential targets for H. pylori infections.
Our aim is to produce new novel nutraceutical formula through provoking the camel immune system to produce enriched milk with H. pylori specific polyclonal antibodies. This will help in the treatment and better control of H. pylori gastric infections and peptic ulcers.back